Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026)
Elanco Animal Health (ELAN) reported Total Non-Current Liabilities of $6.3 billion for Q1 2026, up 2.52% on a YoY basis from $6.1 billion in Q1 2025, and down 3.87% sequentially from $6.5 billion in Q4 2025.
Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Total Non-Current Liabilities data on file, last reported at $6.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 2.52% year-over-year to $6.3 billion; the trailing twelve-month figure through Mar 2026 stood at $6.3 billion (up 2.52% YoY), and the FY2025 full-year result was $6.5 billion, up 4.68% from the prior year.
- Total Non-Current Liabilities fell to $6.3 billion in Q1 2026, from $6.5 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $8.4 billion in Q1 2022 to a low of -$193.0 million in Q2 2022.
- A 5-year average of $6.7 billion and a median of $7.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities tumbled 102.24% in 2022 and surged 4226.94% in 2023, its largest moves.
- Tracing ELAN's Total Non-Current Liabilities over 5 years: stood at $8.0 billion in 2022, then decreased by 3.07% to $7.7 billion in 2023, then declined by 19.57% to $6.2 billion in 2024, then rose by 4.68% to $6.5 billion in 2025, then retreated by 3.87% to $6.3 billion in 2026.
- Business Quant data shows ELAN's Total Non-Current Liabilities at $6.3 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Bn |
| Dec 31, 2025 | 6.51 Bn |
| Sep 30, 2025 | 6.20 Bn |
| Jun 30, 2025 | 6.33 Bn |
| Mar 31, 2025 | 6.10 Bn |
| Dec 31, 2024 | 6.22 Bn |
| Sep 30, 2024 | 6.17 Bn |
| Jun 30, 2024 | 7.36 Bn |
| Mar 31, 2024 | 7.49 Bn |
| Dec 31, 2023 | 7.73 Bn |
| Sep 30, 2023 | 7.78 Bn |
| Jun 30, 2023 | 7.97 Bn |
| Mar 31, 2023 | 8.04 Bn |
| Dec 31, 2022 | 7.97 Bn |
| Sep 30, 2022 | 7.98 Bn |
| Jun 30, 2022 | -193.00 Mn |
| Mar 31, 2022 | 8.40 Bn |
| Dec 31, 2021 | 8.71 Bn |
| Sep 30, 2021 | 8.66 Bn |
| Jun 30, 2021 | 8.62 Bn |